21 CFR Part 820 · Quality System Regulation (before Feb 2, 2026)

21 CFR 820.100

Corrective and preventive action

21 CFR 820.100 is the regulation titled “Corrective and preventive action” in 21 CFR Part 820, Quality System Regulation (before Feb 2, 2026). Since 2021, 105 FDA warning letters have cited it.

Part 820 changed when FDA's Quality Management System Regulation took effect on February 2, 2026. This is the earlier text these letters cite.

Letters citing it
105 since 2021
Jan 1 to Oct 30, 2026
16 against 26 on the same dates in 2025
Most often cited with
21 CFR 820.30, in 80 letters
Closed out
13% of these letters have a published close-out
See the 105 letters citing 21 CFR 820.100 →

Letters citing it, by year issued

Most are medical device letters (104 of 105). 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 112021
  2. 122022
  3. 182023
  4. 192024
  5. 292025
  6. 162026

What FDA writes when it cites it

The finding headings that cite 21 CFR 820.100 most often, as written in the letters.

  • 6 lettersFailure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a)
  • 4 lettersFailure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a)
  • 2 lettersFailure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a)

The regulation

Read the text of 21 CFR 820.100 (eCFR, as of Jun 1, 2025)

(a) Each manufacturer shall establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for:

(1) Analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems;

(2) Investigating the cause of nonconformities relating to product, processes, and the quality system;

(3) Identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems;

(4) Verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device;

(5) Implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems;

(6) Ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems; and

(7) Submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.

(b) All activities required under this section, and their results, shall be documented.

Text from eCFR as of Jun 1, 2025.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 820.100.

Latest letters citing it

The 3 letters citing 21 CFR 820.100 that FDA posted most recently.

See the 105 letters citing 21 CFR 820.100 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.